Introduction: Brain metastasis represents the most common form of intracranial tumor and causes significant morbidity and mortality in cancer patients. This prospective study was carried out at Radiation Oncology Department, Combined Military Hospital Dhaka from January 2010 to December 2012. The concurrent chemotherapy and radiotherapy have shown better outcome and improved the quality of life.
Introduction
Brain metastasis is the most common intracranial tumor in adults. They affect 10-30% of all cancer patients and represent one of the most frequent neurological complications of cancer as a major cause of morbidity and mortality 1,2 . The probability of brain metastasis depends on the type of primary cancer. Lung cancer, malignant melanoma, renal cell carcinoma, breast carcinoma, and colorectal carcinoma are the most common tumors associated with brain metastasis 3 . Many of the patients with lung cancer land with brain metastasis. Most of the brain metastases are detected after the primary tumor has been diagnosed and less frequently brain metastasis appears as the first symptom. Therapeutic options depend on state of the primary tumor, extent of metastasis and performance of the patients. Frequently symptomatic care to relieve neurologic symptoms includes the use of corticosteroids and anticonvulsants 4 . Single brain lesion may be treated by surgery or radiosurgery, in addition to management of the primary tumor. The presence of multiple metastases often preludes the option of surgical resection. In contrast, radiation therapy has been shown to be efficacious in treating brain metastasis regardless of the primary tumor histology, including metastases derived from tumors and suggested for a potential application in combination with radiotherapy as treatment for brain metastases. Studies combining TMZ with whole-brain radiotherapy (WBRT) reported more favorable response rates ranging from 0.176 to 0.959 with median overall survival ranging from 4.1 to 12 months. In these trials, temozolomide might be shown to possess a radiosensitizing effect 10,11 .
The concurrent use of TMZ and WBRT is well tolerated and higher response rate is achieved in patients receiving TMZ and radiotherapy versus radiotherapy alone 12,13 confirming the combination of TMZ with radiation 14 . The primary aim of this study was to assess the efficacy and safety of the combination of TMZ and WBRT in patients with brain metastasis at our hospital setup.
Materials and Methods
This prospective study was carried out at Radiation Oncology Department, Combined Military Hospital, Dhaka from January 2010 to December 2012. The study population consisted of 60 cancer patients with brain metastasis. Data were collected from the patients in predesigned informed sheets and also from their documents. Patient eligibility criteria: adult patients with histologically proven primary cancer with measurable multiple brain metastasis assessable by contrast-enhanced computed tomography scan or gadolinium enhanced magnetic resonance imaging (MRI) that were not suitable for surgery or radiosurgery, were eligible for the study.
Other eligibility criteria included age ≥18 years; Karnofsky performance status (KPS) ≥50. Eligible patients were required to be fully recovered from previous therapy.
Treatment schedule
Planned conventional WBRT was administrated with a daily dose of 3 Gy × 5 days each week for two weeks to a total dose of 30 Gy (Fig-I) . TMZ was administrated orally at a dosage of 75 mg/m²/day during the radiation. Treatment was continued until unacceptable toxicity. All patients received corticosteroids at the dose necessary to maintain neurologic stability, and anti-convulsants were given when indicated.
Patient evaluation
Primary end point of the study was symptom relief and secondary endpoints were objective responses six weeks after the end of concurrent TMZ and WBRT. Baseline assessments were performed before the initiation of radiation treatment. All patients underwent weekly physical and neurologic examinations during concurrent treatment and a complete clinical evaluation, laboratory tests, KPS and CT or MRI 45 days after WBRT. Objective response was evaluated according to the WHO criteria 15 .
Results
Among 60 patients incidence was more in older patients. Number of male patients were more than female ( Table-I) . The prominant symptoms were as per Table-III.  Table- III: Symptoms before WBRT and TMZ (n=60).
Most of the patients got symptomatic relief after treament ( Table-IV) . Table- IV: Symptom relief after WBRT and TMZ (n=60).
Objective response after treatment were encouraging (Table-V & Fig-2) . Table- V: Objective response after WBRT and TMZ (n=60).
The concurrent TMZ and WBRT were well tolerated in almost all patients. Most side effects were of grade 2 and well controlled by supportive care ( Table-VI) . Table- VI: Treatment related toxicities (n=60).
Fig-1:
Radiotherapy of whole brain. 
Fig-2: MRI of brain metastasis -before (up) & 1½ months after treatment (down).

Conclusion
The present study supports the feasibility, efficacy and safety of concurrent use of WBRT and TMZ in the treatment of patients with brain metastasis at our hospital setup. The outcome observed in this study was found comparable with similar studies abroad. The presented data looks promising and this needs to be further validated within the settings of a randomized trial. The use of WBRT in brain metastasis appears unlikely to be replaced by other therapies in the near future, and thus the clinical trials that are currently attempting to improve the efficacy and toxicity profiles of WBRT will have the potential for strong clinical application.
